Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: The role of cytokines produced by obese-derived adipose tissue, namely adipokines, in the pathophysiology of osteoarthritis (OA) is now well established. We recently suggested that one of them, visfatin, may play a role in OA by activating chondrocytes (1,2). Along with its cytokine effect, visfatin has an enzymatic activity called nicotinamide phosphoribosyltransferase (Nampt), which is the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide (NAD) biosynthesis from nicotinamide, an intracellular pathway involved in many biological processes including TNFα and IL-6 synthesis. Thus, we aimed to i) characterize the local site(s) of production of visfatin/Nampt by the human OA joint tissues ii) further investigate the role of its enzymatic activity in the expression of pro-inflammatory cytokines by chondrocytes and iii) determine whether visfatin/Nampt may also play a role in subchondral bone.
Methods: Human OA joint tissues (synovial membrane, cartilage, subchondral bone) from patients undergoing surgical knee replacement were incubated for 24h in serum-free media. Visfatin/Nampt release in media by the different tissues was evaluated using Western Blot and ELISA. Primary cultures of mouse chondrocytes and osteoblasts were stimulated with recombinant visfatin/Nampt (5µg/mL) for 24h. To determine the role of the enzyme activity, cells were pretreated or not 4h before visfatin/Nampt stimulation with APO866 (10nM), a pharmacologic inhibitor of Nampt activity (3). Effects of stimulation on IL-6, IL-8/Kc, IL-1β, MCP-1, VEGF and TGFβ expression, and on IL-6 and IL-8/Kc release were examined by quantitative RT-PCR and ELISA, respectively.
Results: All human OA joint tissues released visfatin/Nampt (synovium: 529 ± 356, cartilage: 237 ± 380, subchondral bone: 200 ± 104 ng/g tissue) with higher level for the synovium compared to cartilage (p<0.01). Visfatin/Nampt significantly induced IL-6, IL-8/Kc, IL-1β and MCP-1 expression by chondrocytes (n=6) and osteoblasts (n=5) (Table). Visfatin/Nampt increased the production of IL-6 and IL-8/Kc proteins by both cell types. Nampt activity inhibition by APO866 decreased pro-inflammatory cytokines expression at mRNA level (up to 97 % of inhibition) as well as at protein level (up to 63 % of inhibition) and was especially efficient in chondrocytes (Table). Effect of visfatin/Nampt was selective since VEGF and TGFβ were not modulated upon stimulation.
|
Gene expression |
Protein production |
|||||
IL-6 |
Kc/IL-8 |
IL-1β |
MCP-1 |
IL-6 |
Kc/IL-8 |
||
Chondrocytes (n=6) |
Fold induction after visfatin/Nampt stimulation (Mean ± SEM), p-value |
10.6 ± 3 (p=0.015) |
4.9 ± 1.3 (p=0.015) |
878 ± 320 (p=0.015) |
2.5 ± 0.4 (p=0.03) |
5.8 ± 5 (p=0.016) |
29.7 ± 33 (p=0.015) |
Mean % of inhibition by APO866 |
94 % |
83 % |
97 % |
62 % |
63 % |
57% |
|
Osteoblasts (n=5) |
Fold induction after visfatin/Nampt stimulation (Mean ± SEM), p-value |
296 ± 59 (p=0.03) |
142 ± 64 (p=0.03) |
396 ± 112 (p=0.03) |
133 ± 83 (p=0.03) |
51 ± 19 (p=0.05) |
54 ± 23 (p=0.05) |
Mean % of inhibition by APO866 |
63 % |
79 % |
73 % |
84 % |
39 % |
49% |
Conclusion: Visfatin/Nampt is produced by the cartilage, the subchondral bone and mostly by the synovial membrane. We demonstrate that Nampt activity of visfatin plays a major role in chondrocytes and osteoblasts activation, suggesting that targeting the Nampt enzymatic activity with a compound like APO866 (being tested in hematological malignancies) may be a new therapeutic approach of OA.
References: (1)Gosset M. Arthritis Rheum 2008 (2) Jacques C. J Biol Chem 2012 (3) Busso N. PLoS One 2008
Disclosure:
M. C. Laiguillon,
None;
C. Bougault,
None;
X. Houard,
None;
M. Gosset,
None;
G. Nourissat,
None;
S. Priam,
None;
Z. Mladenovic,
None;
C. Jacques,
None;
F. Berenbaum,
None;
J. Sellam,
None.
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/visfatinnampt-in-osteoarthritis-sites-of-production-in-human-joints-and-role-of-its-enzymatic-activity/